Phase I Study of FT538 Monotherapy and in Combination with Vorinostat for the Treatment of Persistent Low-Level HIV Viremia
|Effective start/end date||7/11/22 → 7/31/28|
- FATE THERAPEUTICS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.